さまざまな薬剤の治療効果を調査する慢性腎臓病適応プラットフォーム試験 (CAPTIVATE)
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).
CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.
CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.
CAPTIVATE includes multiple domains examining different therapies for CKD. Participants may enrol in one or more domains and domains will be added and closed over time. The platform operates under a core protocol with each domain described in a domain specific appendix.
調査の概要
詳細な説明
Chronic kidney disease (CKD) affects over 800 million people globally and is projected to be the 5th most common cause of death by 2040. CKD progresses to kidney failure, increases the risk of early death, heart disease, and leads to a poorer quality of life.
Current treatments do not entirely remove the risk of kidney failure in people with CKD. To improve the outcomes of people with CKD, it is crucial to find the best treatment or combination of treatments that can slow CKD progression. CAPTIVATE aims to address this need.
CAPTIVATE has been designed to test multiple treatments within a common research platform. This design is more efficient and will lead to a shorter time for patients to receive effective treatments. The trial is 'eternal', which means that participants will continue to be recruited for many years until the trial is finally wound up. It is also 'adaptive', providing the flexibility to add new treatments, or remove those that are not working.
Participants can participate in more than one treatment at the same time or at different times. Participants receive each study treatment for 2 years. For each treatment, participants are followed up at study visits that occur at approximately one month, 3 months, 6 months, 12 months, 18 months and 2 years after starting treatment. A final study visit occurs one month after the end of the 2-year treatment phase. Information collected at study visits include blood and urine test results, safety assessments and treatment adherence. Information about the overall health status of each participant is collected every 5 years.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Enmoore Lin
- 電話番号:61 2 8052 4511
- メール:captivate@georgeinstitute.org.au
研究場所
-
-
-
Dehradun、インド、248001
- まだ募集していません
- Max Superspeciality Hospital, Dehradun
-
コンタクト:
- Puneet Arora
-
Ghaziabad、インド、201012
- 募集
- Max Superspecialty Hospital, Ghaziabad
-
コンタクト:
- Manoj Kumar Singhal
-
Puducherry、インド、607403
- 募集
- Aarupadai Veedu Medical College & Hospital (AVMCH), Puducherry
-
コンタクト:
- Venkatesh A
-
-
Andhra Pradesh
-
Visakhapatnam、Andhra Pradesh、インド、530045
- 募集
- Gitam Institute of Medical Sciences and Research
-
コンタクト:
- Murty Mandapaka
-
-
Bihar
-
Patna、Bihar、インド、800001
- 募集
- Patna Medical College and Hospital
-
コンタクト:
- Harsh Vardhan
-
-
Chhattisgarh
-
Raipur、Chhattisgarh、インド、492002
- 募集
- DKS Super Speciality Hospital, Raipur
-
コンタクト:
- Varun Agrawal
-
-
Dehradun
-
Dehradun、Dehradun、インド、248001
- 募集
- Mysore Medical College
-
コンタクト:
- Puneet Arora
-
-
Gujarat
-
Ahmedabad、Gujarat、インド、380025
- 募集
- GCS Medical College, Hospital & Research Centre
-
コンタクト:
- Suvika Patel
-
Vadodara、Gujarat、インド、390007
- 募集
- Aman Hospital & Research Center Vadodara
-
コンタクト:
- Aman Khanna
-
-
Karnataka
-
Mangaluru、Karnataka、インド、575002
- 募集
- Father Muller Medical College Hospital
-
コンタクト:
- Manjunath Kulkarni
-
-
Kerala
-
Meppādi、Kerala、インド、673511
- 募集
- Dr Moopen's Medical College
-
コンタクト:
- Aneesh Basheer
-
-
Madhya Pradesh
-
Indore、Madhya Pradesh、インド
- 募集
- CARE-CHL Hospital
-
コンタクト:
- Isha Tiiwari
-
-
Tamil Nadu
-
Chennai、Tamil Nadu、インド、600024
- 募集
- Medway Hospital
-
コンタクト:
- Shivakumar Dakshinamoorthy
-
-
Telangana
-
Hyderabad、Telangana、インド、500084
- 募集
- Yashoda Hospital Hitec City
-
コンタクト:
- Mahesh Kota
-
Hyderabad、Telangana、インド
- 募集
- Apollo Hospitals
-
コンタクト:
- Haresh Patel
-
-
Uttar Pradesh
-
Lucknow、Uttar Pradesh、インド、226003
- 募集
- Charak Hospital and Research Centre
-
コンタクト:
- Sakshi Jain
-
-
Uttarakhand
-
Dehradun、Uttarakhand、インド、248001
- 募集
- Shri Guru Ram Rai Medical College and Shri Mahant Indiresh Hospital
-
コンタクト:
- Gaurav Shekhar Sharma
-
-
West Bengal
-
Kolkata、West Bengal、インド、700107
- 募集
- Fortis Hospital
-
コンタクト:
- Upal Sengupta
-
Siliguri、West Bengal、インド、734012
- 募集
- North Bengal Medical College & Hospital
-
コンタクト:
- Arpita Ray Chaudhury
-
-
-
-
Australian Capital Territory
-
Garran、Australian Capital Territory、オーストラリア、2605
- 募集
- The Canberra Hospital
-
コンタクト:
- Girish Talaulikar
-
-
New South Wales
-
Kingswood、New South Wales、オーストラリア、2747
- 募集
- Nepean Blue Mountains Local Health District
-
コンタクト:
- Bhadran Bose
-
Kogarah、New South Wales、オーストラリア、2217
- 募集
- St George Hospital
-
コンタクト:
- Sunil Badve
-
New Lambton Heights、New South Wales、オーストラリア、2305
- 募集
- John Hunter Hospital
-
コンタクト:
- Bobby Chacko
-
Westmead、New South Wales、オーストラリア、2145
- 募集
- Westmead Hospital
-
コンタクト:
- Vincent Lee
-
-
Queensland
-
Birtinya、Queensland、オーストラリア、4575
- 募集
- Sunshine Coast Hospital and Health Service
-
コンタクト:
- Nicholas Gray
-
Douglas、Queensland、オーストラリア、4814
- 募集
- Townsville University Hospital
-
コンタクト:
- Vikas Srivastava
-
Ipswich、Queensland、オーストラリア、4305
- 募集
- West Moreton Hospital & Health Service
-
コンタクト:
- Sree Venuthurupalli
-
Southport、Queensland、オーストラリア、4215
- 募集
- Gold Coast Hospital and Health Service
-
コンタクト:
- Jagadeesh Kurtkoti
-
-
South Australia
-
Adelaide、South Australia、オーストラリア、5000
- 募集
- Royal Adelaide
-
コンタクト:
- Michael Collins
-
Elizabeth Vale、South Australia、オーストラリア、5112
- 募集
- Lyell McEwin Hospital
-
コンタクト:
- Nitesh Rao
-
-
Victoria
-
Heidelberg、Victoria、オーストラリア、3084
- 募集
- Austin Health
-
コンタクト:
- Sharon Ford
-
-
Western Australia
-
Murdoch、Western Australia、オーストラリア、6150
- 募集
- South Metropolitan Health Service, Fiona Stanley Hospital
-
コンタクト:
- Suda Swaminathan
-
-
-
-
Barcelona
-
Badalona、Barcelona、スペイン、08916
- 積極的、募集していない
- Hospital Germans Trias i Pujol
-
Horta-Guinardó、Barcelona、スペイン、08035
- 募集
- Vall d'Hebron University Hospital
-
コンタクト:
- Dr Maria Jose Soler Romeo
-
-
Espana
-
Valencia、Espana、スペイン、46010
- 募集
- Hospital Clinico Universitario València (INCLIVA)
-
コンタクト:
- Prof Jose Luis Gorriz Teruel
-
-
-
-
-
Colombo、スリランカ、00700
- 募集
- National Hospital of Sri Lanka
-
コンタクト:
- Dr Mathu Selvarajah
-
Kandy、スリランカ、20000
- 募集
- Kandy National Hospital
-
コンタクト:
- Dr Nishantha Nanayakkara
-
Kurunegala、スリランカ
- 募集
- Kurunegala Teaching Hospital
-
コンタクト:
- Dr Premil Rajakrishnan
-
Nugegoda、スリランカ、10250
- 募集
- Sri Jayewardenepura General Hospital
-
コンタクト:
- Dr Harshani Perera
-
Peradeniya、スリランカ、20400
- 募集
- Peradeniya Teaching Hospital
-
コンタクト:
- Dr Rajitha Abeysekera
-
Ragama、スリランカ、11010
- 募集
- Colombo North Teaching Hospital
-
コンタクト:
- Dr Nalaka Herath
-
-
Northern Province
-
Jaffna、Northern Province、スリランカ、4000
- 募集
- Jaffna Teaching Hospital
-
コンタクト:
- Dr. Brammah Thangarajah
-
-
Polonnaruwa
-
Colombo、Polonnaruwa、スリランカ、51000
- 募集
- National Nephrology Specialized Hospital
-
コンタクト:
- Dr Naseef Thaseem
-
-
Western Province
-
Dehiwala、Western Province、スリランカ、10290
- 募集
- University Hospital, Kotelawala Defence University
-
コンタクト:
- Dr Dilukshi Pilapitiya
-
-
-
-
-
Auckland、ニュージーランド、1023
- 募集
- Auckland City Hospital
-
コンタクト:
- Dr Helen Pilmore
-
Auckland、ニュージーランド、2025
- 募集
- Aotearoa Clinical Trials Trust, Middlemore Hospital
-
コンタクト:
- Kalpa Jayanatha
-
Auckland、ニュージーランド、0620
- 募集
- Health New Zealand, Te Whatu Ora Waitemata, North Shore Hospital
-
コンタクト:
- Ashik Hayat
-
Dunedin、ニュージーランド、9016
- 募集
- 201 Great King Street, Central Dunedin, Dunedin 9016, New Zealand
-
コンタクト:
- John Schollum
-
Palmerston North、ニュージーランド、4442
- 募集
- Midcentral - Palmerston North Hospital
-
コンタクト:
- Dr Curtis Walker
-
Whangarei、ニュージーランド、0148
- 募集
- Private Bag 9742 Maunu Road, Horahora, Whangārei 0148, New Zealand
-
コンタクト:
- Adam Mullan
-
-
Hawkes Bay
-
Hastings、Hawkes Bay、ニュージーランド、4120
- 募集
- Health New Zealand, Te Whatu Ora Te Matau a Maui, Hawke's Bay Hospital
-
コンタクト:
- Hussain Allawati
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥ 18 years
- Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m2)
- Currently receiving standard of care treatment according to treating physician
- Eligible for randomisation in at least one recruiting domain-specific appendix
- Participant and treating physician are willing and able to perform trial procedures
Exclusion Criteria:
- Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
- Life expectancy less than 6 months
To be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above)
MRA domain
Inclusion Criteria:
- Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine protein-creatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
- On a stable standard of care treatment for CKD, including a SGLT2i unless there is a documented reason not to be using a SGLT2i*, for 4 weeks before screening according to treating physician.
- Treating physician believes finerenone is clinically appropriate for the participant.
- Participant and treating physician are willing and able to perform MRA DSA procedures.
- Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any MRA DSA related procedures
Exclusion Criteria:
- Recipient of kidney transplant
- Hyperkalaemia (serum potassium ≥5.0 mmol/L) at time of screening
- Current treatment with MRA, where the treating physician or patient is not willing to discontinue this medication. If willing to discontinue the MRA, the potential participant must be re-screened after they have been on stable standard of care treatment for 4 weeks without the MRA.
- Known allergy, intolerance or contraindication to MRAs
- Current treatment with strong CYP3A4 inhibitors
- Systolic BP <110 mmHg or diastolic BP<55 mmHg without antihypertensive therapy at time of screening
- Severe hepatic impairment (defined as Child-Pugh Class C)
- Adrenal insufficiency
- Currently pregnant or breast feeding, or intending to become pregnant
GLP-1 RA Domain
Inclusion Criteria
- Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine proteincreatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
- On a stable standard of care treatment for CKD, including a SGLT2i and maximum tolerated ACEi/ARB unless there is a documented reason not to be using a SGLT2i, for 4 weeks before screening.
- HbA1c less than or equal to 10% (less than or equal to 86mmol/L)
- BMI ≥23 kg/m2 and < 50 kg/m2
- Treating physician believes semaglutide is clinically appropriate for the participant
- Participant and treating physician are willing and able to perform GLP-1 RA DSA procedures
- Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any GLP-1 RA DSA related procedures
Exclusion Criteria
- Recipient of kidney transplant
- Major adverse cardiovascular events (MACE), consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, within 90 days prior to the day of screening
- Presently classified as being in New York Heart Association (NYHA) Class IV heart failure
- Personal or first-degree relative(s) with a history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)
- Previous episode of pancreatitis
- Uncontrolled thyroid disease TSH>6.0 mIU/L or <0.4mlU/L
- Type 1 diabetes
- Current treatment with a GLP-1 RA, where it is in the participant's best interests to continue the GLP-1 RA or where the treating physician or patient is not willing to discontinue this medication for a minimum of 4 weeks prior to randomisation and for the full duration of the trial (ie. 108 weeks if assigned to placebo).
- Known allergy, intolerance, or contraindication to GLP-1 RAs
- Currently pregnant or breast feeding, or intending to become pregnant or is of child-bearing potential, and not using a highly effective contraceptive method
- Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:階乗代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Finerenone
Finerenone 10mg or 20mg tablets |
Finerenone 10mg or 20mg tablets, oral, once daily
他の名前:
|
|
プラセボコンパレーター:Placebo Finerenone
Finerenone matched placebo tablets |
Finerenone matched placebo tablets, oral, once daily |
|
実験的:Semaglutide
Semaglutide 1.0 mg or 2.4 mg pen injector |
Semaglutide 1.0mg or 2.4mg pen injector, subcutaneous injection, once weekly |
|
プラセボコンパレーター:Placebo Semaglutide
Semaglutide matched placebo pen injector |
Semaglutide matched pen injector, subcutaneous injection, once weekly |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Core Primary Outcome Measure
時間枠:From randomisation to week 108
|
The primary outcome is chronic eGFR slope. Chronic eGFR slope measures the rate of eGFR decline while on treatment. The duration of time over which chronic eGFR slope is computed can vary by domain and is determined by clinical considerations such as whether the investigational product can cause an acute decline in eGFR upon initiation. DSAs will specify the duration of time over which chronic eGFR slope is computed for the individual domain. |
From randomisation to week 108
|
|
MRA Domain Primary Outcome Measure
時間枠:From week 4 to week 108
|
Chronic eGFR slope estimated from all available eGFR values from week 4 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment. |
From week 4 to week 108
|
|
GLP1-RA Domain Primary Outcome Measure
時間枠:From week 0 to week 108
|
Chronic eGFR slope estimated from all available eGFR values from Week 0 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment. |
From week 0 to week 108
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Core Protocol Secondary outcomes
時間枠:week 0 and 24 weeks
|
1. Change in albuminuria as measured by uACR (or uPCR if uACR unavailable) between week 0 and 24 weeks, measured as a continuous variable. |
week 0 and 24 weeks
|
|
Core Protocol Secondary outcomes
時間枠:week 0 to end of washout
|
2. eGFR slope from week 0 to end of washout |
week 0 to end of washout
|
|
Core Protocol Secondary outcomes
時間枠:week 0 to end of washout
|
3. Change in eGFR from week 0 to end of washout |
week 0 to end of washout
|
|
Core Protocol Secondary outcomes
時間枠:between week 0 and 108 weeks
|
4. Composite outcome of proportion of participants experiencing a ≥40% eGFR decline between week 0 and 108 weeks, and proportion of participants developing kidney failure (defined as eGFR <15 mL/min/1.73m2 or chronic kidney replacement therapy start†) at 108 weeks. |
between week 0 and 108 weeks
|
|
Core Protocol Secondary outcomes
時間枠:from start of study drug (week 0) to washout (week 108) or kidney failure
|
5. Time to a composite outcome of ≥40% eGFR decline from week 0 or kidney failure |
from start of study drug (week 0) to washout (week 108) or kidney failure
|
|
Core Protocol Secondary outcomes
時間枠:at 108 weeks
|
6. All-cause mortality at 108 weeks |
at 108 weeks
|
|
Core Protocol Secondary outcomes
時間枠:between week 0 and week 108
|
7. Proportion of participants experiencing one or more cardiovascular events (cardiovascular death, hospitalised heart failure, myocardial infarction, stroke)* between week 0 and week 108 |
between week 0 and week 108
|
|
Core Protocol Secondary outcomes
時間枠:from start of study drug (week 0) to end of washout (week 108)
|
8. Time to first occurrence of a cardiovascular event |
from start of study drug (week 0) to end of washout (week 108)
|
|
Core Protocol Secondary outcomes
時間枠:from start of study drug (week 0) to end of treatment (up to week 104)
|
9. Safety and tolerability of treatment |
from start of study drug (week 0) to end of treatment (up to week 104)
|
|
Core Protocol Secondary outcomes
時間枠:6-monthly intervals from randomisation to week 108
|
10. Change in quality of life measured using the Quality of Life Impact Survey for Kidney Disease (QDISCKD) at 6-monthly intervals from randomisation to week 108. |
6-monthly intervals from randomisation to week 108
|
|
MRA Domain Secondary Outcome
時間枠:from start of study drug (week 0) to end of washout (week 108)
|
MRA DSA has a domain-specific secondary outcome that evaluates the time to the composite of ≥57% eGFR decline from week 0 or kidney failure |
from start of study drug (week 0) to end of washout (week 108)
|
|
GLP-1 RA Domain Secondary Outcome
時間枠:from start of study drug (week 0) to end of washout (week 108)
|
1. Change in eGFR slope from Week 0 to Week 108. |
from start of study drug (week 0) to end of washout (week 108)
|
|
GLP-1 RA Domain Secondary Outcome
時間枠:from start of study drug (week 0) to end of washout (week 108)
|
2. Time to composite of onset of kidney failure (initiation of long-term dialysis, kidney transplantation, or a reduction in the eGFR to <15 mL per minute per 1.73 m2 sustained for ≥28 days), a sustained (for ≥28 days) 50% or greater reduction in eGFR from Week 0, or death from kidney-related or cardiovascular causes. |
from start of study drug (week 0) to end of washout (week 108)
|
|
GLP-1 RA Domain Secondary Outcome
時間枠:from Week 0 to Week 108
|
3. Time to first occurrence of onset of persistent ≥50% reduction in eGFR from Week 0 to Week 108 |
from Week 0 to Week 108
|
|
GLP-1 RA Domain Secondary Outcome
時間枠:from start of study drug (week 0) to end of washout (week 108)
|
4. Time to first occurrence of a composite outcome of major adverse cardiovascular events (MACE) consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death |
from start of study drug (week 0) to end of washout (week 108)
|
|
GLP-1 RA Domain Secondary Outcome
時間枠:from start of study drug (week 0) to end of washout (week 108)
|
5. Time to occurrence of all-cause death |
from start of study drug (week 0) to end of washout (week 108)
|
|
GLP-1 RA Domain Secondary Outcome
時間枠:from Week 0 to Week 108
|
6. Change in body weight from Week 0 to Week 108 |
from Week 0 to Week 108
|
|
GLP-1 RA Domain Secondary Outcome
時間枠:Week 0 to Week 108
|
7. Change in HbA1c from Week 0 to Week 108 |
Week 0 to Week 108
|
|
GLP-1 RA Domain Secondary Outcome
時間枠:from Week 0 to Week 108
|
8. Change in systolic blood/diastolic blood pressure from Week 0 to Week 108 |
from Week 0 to Week 108
|
|
GLP-1 RA Domain Secondary Outcome
時間枠:from Week 0 to Week 108
|
9. Change in NT-proBNP from Week 0 to Week 108 |
from Week 0 to Week 108
|
|
GLP-1 RA Domain Secondary Outcome
時間枠:from randomisation to Week 108
|
10. Change in health status measured using the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ) at 6-monthly intervals from randomisation to Week 108 |
from randomisation to Week 108
|
|
GLP-1 RA Domain Secondary Outcome
時間枠:Week 0 to end of trial
|
11. Incidence of AEs and the following medical events of special interest (MESI) from Week 0 to end of trial:
|
Week 0 to end of trial
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Sradha Kotwal、The George Institute
- スタディチェア:Hiddo Lambers Heerspink、The George Institute
出版物と役立つリンク
一般刊行物
- Kotwal SS, Perkovic V, Jardine MJ, Kim D, Shah NA, Lin E, Coggan S, Billot L, Vart P, Wheeler DC, de Boer IH, Zhang H, Hou FF, Sugawara Y, Marion J, Lewis RJ, Berry LR, McGlothlin A, Jha V, De Nicola L, Gorriz JL, Heerspink HJL; GKPTN and CAPTIVATE Investigators. The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol. JAMA Netw Open. 2024 Dec 2;7(12):e2449998. doi: 10.1001/jamanetworkopen.2024.49998.
- Heerspink HJL, Kretzler M. Clinical Trials for Kidney Disease in the Era of Personalized Medicine. J Am Soc Nephrol. 2024 Aug 1;35(8):1123-1126. doi: 10.1681/ASN.0000000000000412. Epub 2024 May 9. No abstract available.
- Yeung EK, Rangaswami J, Tuttle KR, Grams ME, Tangri N, Vaduganathan M, Neuen BL. A Framework for Risk-Based Implementation of Combination Therapy in CKD: Who, Why, When, and How? Clin J Am Soc Nephrol. 2026 Jun 23. doi: 10.2215/CJN.0000001158. Online ahead of print.
- Shah NA, Du R, Neuen BL, Levin A, Jha V, Heerspink HJL, Kotwal SS; CAPTIVATE investigators. A Dose of Perspective: A Multinational Survey of Patient and Clinician Views on Combination Therapy in CKD. Kidney360. 2026 Aug 1;7(8):1772-1780. doi: 10.34067/KID.0000001227. Epub 2026 Jun 2.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- P01351
- U1111-1324-3113 (その他の識別子:World Health Organisation, Universal Trial Number (UTN))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Trial data will be made available as a resource for future unspecified research, subject to any prior contractual obligations. Researchers wishing to gain access to the study resources will be required to submit an application for review by the Platform Oversight Committee, including a detailed project description, a list of data requested, and evidence of ethical approval. De-identified data extracts will be made available to approved proposals, and will not include data obtained from data linkage with local registries.
IPD 共有時間枠
TBC
IPD 共有アクセス基準
Assessments of data requests will be based on sound science, benefit-risk balancing and research team expertise.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。